Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.56 |
| ▸ | BRD4 | O60885 | 11/20 | 0.49 |
| ▸ | BRD2 | P25440 | 3/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116271 | 0.73 | BRD4 (0.53) | ERN1BRD4BRD2CREBBPALDH1A1 | |
| SCHEMBL3104665 | 0.73 | POLB (0.36) | ERN1BRD4BRD2BRD3CREBBP | |
| SCHEMBL12766791 | 0.72 | ERN1 (1.00) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL6040649 | 0.71 | ERN1 (0.59) | ERN1BRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL2498903 | 0.70 | BRD4 (0.53) | ERN1BRD4BRD2CREBBPCYP1A2 | |
| SCHEMBL8326046 | 0.70 | ERN1 (0.72) | ERN1BRD4BRD2BRD3 | |
| SCHEMBL12767795 | 0.69 | ERN1 (1.00) | ERN1BRD4BRD2BRD3CREBBP | |
| SCHEMBL15600597 | 0.69 | ERN1 (0.86) | ERN1BRD4BRD2BRD3CREBBP | |
| SCHEMBL12767020 | 0.68 | ERN1 (1.00) | ERN1 | |
| SCHEMBL18359658 | 0.68 | ERN1 (0.55) | ERN1BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | ERN1 1620/4885BRD4 90/4885BRD2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.